Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.
Latest from Adam Zamecnik
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.
Marking another step in Dr Reddy’s diverse corporate strategy, the company has signed a memorandum of understanding with Kainomyx for the development and commercialization of anti-malarials in multiple markets.
After a transformative last fiscal year, Sawai presented its financial first quarter results for its 2025 year, with slight disappointment among analysts due to missed revenue forecasts.
Following Towa’s reveal of its medium-term business plan earlier this year, the company has shared its financial first quarter results, which were positively received by select analysts.
Doubling down on its Latin American strategy, Zydus has managed to snap up a second biosimilar approval in Mexico, paving the way for future launches.
Following past approvals for Alvotech and Amgen, Health Canada greenlighted Celltrion’s Stelara biosimilar in most of the relevant indications, moving it ahead of Alvotech’s product.